[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623142":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":34,"centralContacts":48,"locations":27,"responsibleParty":57,"collaborators":27,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":27,"enrollmentInfo":69,"targetDuration":27,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":85,"whyStopped":27,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":27},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Besancon","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","* Early initiation of dapagliflozin 10mg daily within 24h of ED admission\n* Telephone follow-up by cardiac nurse practitioner at 1 month\n* Standard acute decompensated heart failure care",[13,14,15],"Drug: Early initiation of dapagliflozin 10mg daily within 24h of emergency department admission","Other: Telephone follow-up by cardiac nurse practitioner at 1 month","Other: Standard acute decompensated heart failure care",{"label":17,"type":18,"description":19,"interventionNames":20},"Control group","ACTIVE_COMPARATOR","✓ Standard acute decompensated heart failure care ONLY",[15],[22,28,31],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Early initiation of dapagliflozin 10mg daily within 24h of emergency department admission","Early initiation of dapagliflozin 10mg daily within 24h of ED admission",[9],null,{"type":6,"name":29,"description":29,"armGroupLabels":30,"otherNames":27},"Telephone follow-up by cardiac nurse practitioner at 1 month",[9],{"type":6,"name":32,"description":32,"armGroupLabels":33,"otherNames":27},"Standard acute decompensated heart failure care",[17,9],[35,39,41,43,46],{"name":36,"affiliation":37,"role":38},"Fatimata SARR, PhD","CHU Besançon","STUDY_CHAIR",{"name":40,"affiliation":37,"role":38},"Frédéric MAUNY, MD, PhD",{"name":42,"affiliation":37,"role":38},"Marc PUYRAVEAU, MSc",{"name":44,"affiliation":45,"role":38},"Thibaut DESMETTRE, MD, PhD","University Hospital, Geneva",{"name":47,"affiliation":37,"role":38},"Johan COSSUS, MD",[49,54],{"name":50,"role":51,"phone":52,"phoneExt":27,"email":53},"Omide TAHERI, MD, PhD","CONTACT","03 81 66 70 28","omide.taheri@gmail.com",{"name":55,"role":51,"phone":27,"phoneExt":27,"email":56},"Marie-France SERONDE, MD, PhD","marie-france.seronde2@univ-fcomte.fr",{"type":58,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100623142","early-gliflozin-for-elderly-patients-with-acute-decompensated-heart-failure-in-the-emergency-department-100623142",false,"NCT07392788","Early Gliflozin for Elderly Patients With Acute Decompensated Heart Failure in the Emergency Department","Early Gliflozin Treatment in Elderly Patient Hospitalized for Decompensated Chronic Heart Failure Admitted in the Emergency Room - a Feasibility Study","GlifloFastER","Inclusion Criteria:\n\n1. Age ≥ 75 years\n2. ED admission for ADCHF with:\n\n   * Worsening CHF symptoms (dyspnea, fatigue, weight gain, edema)\n   * Objective signs of peripheral\u002Fpulmonary congestion\n   * Elevated natriuretic peptides:\n\n     * Sinus rhythm: BNP ≥ 400 pg\u002FmL or NT-proBNP ≥ 1,600 pg\u002FmL\n     * Atrial fibrillation: BNP ≥ 600 pg\u002FmL or NT-proBNP ≥ 2,400 pg\u002FmL\n   * Need for treatment intensification\n3. Expected hospitalization\n4. No prior gliflozin treatment\n5. Signed informed consent\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* Chronic kidney disease (eGFR \\\u003C 25ml\u002Fmin\u002F1.73m²)\n* Cardiogenic shock\n* Acute coronary syndrome (current or within 30 days)\n* Severe valvular disease requiring surgery\n* Recent\u002Fplanned coronary intervention\n* Known intolerance to study medication\n* Legal protection measure or inability to consent\n* Hospitalization in cardiology department\n* Discharge home or to nursing home","ALL","75 Years",{"count":70,"type":71},144,"ESTIMATED","INTERVENTIONAL",[74],"NA","Background: SGLT2 inhibitors reduce CHF morbidity\u002Fmortality but are underutilized in elderly patients with acute decompensated CHF (ADCHF) admitted outside cardiology departments.\n\nObjective: Assess feasibility of early ED-initiated gliflozin therapy in elderly ADCHF patients.\n\nDesign: Multicenter, randomized, open-label pilot study; N=144 patients (72 per arm) across 6 EDs over 30 months.\n\nPopulation: Age ≥75 years, ED admission for ADCHF (symptomatic worsening, congestion, elevated natriuretic peptides), gliflozin-naïve, requiring hospitalization.\n\nKey Exclusions: Type 1 diabetes, eGFR \\\u003C25 mL\u002Fmin\u002F1.73m², cardiogenic shock, recent ACS, cardiology ward admission.\n\nIntervention:\n\nTreatment: Dapagliflozin 10mg daily within 24h + cardiac nurse telephone follow-up at 1 month Control: Standard care only Primary Outcome: Feasibility (organizational implementation, acceptability, protocol adherence, timeline compliance).\n\nFollow-up: 7-day visit (clinical assessment, NT-proBNP, echocardiography) and 3-month cardiology consultation (mortality, rehospitalization, QoL, biomarkers, safety parameters).",[77],"Acute Heart Failure (AHF)",[79,80,81,82,83,84],"acute heart failure","emergency department","elderly","SGLT2 Inhibitors","Feasibility study","Acute Decompensated Chronic Heart Failure","NOT_YET_RECRUITING","2026-02-05",{"date":88,"type":89},"2026-02-06","ACTUAL",{"date":91,"type":71},"2026-04",{"date":93,"type":71},"2028-02",{"name":5,"class":6}]